Contract facts
FederalNo full NAICS 325414 intel page yet. Browse NAICS intelligence
Duns Number: 167380711 Uei: FRHTPHMZMX47 the Purpose of This Modification Is to Activate the Invoice Processing Platfor… is a federal award for Barda - Aspr / Daappo / Barda Dcma held by Glaxosmithkline LLC. Estimated value $18.2M ($84K obligated). Current period of performance ends Mar 31, 2025. Last award drew 1 bidder. Place of performance: DURHAM NC. Related solicitation 15100SOL00003.
Duns number: 167380711 uei: frhtphmzmx47 the purpose of this modification is to activate the invoice processing platform (ipp) for this task order in the government's contracting writing system. this modification does not affect funding or c
Recompete timing
PublicCurrent PoP ended Mar 31, 2025 (588 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on 75A50119F33009? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordGlaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50119F33009?
75A50119F33009 (Duns number: 167380711 uei: frhtphmzmx47 the) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $18.2M, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50119F33009?
Barda - Aspr / Daappo / Barda Dcma awarded 75A50119F33009 to Glaxosmithkline LLC (potential $18.2M).
Who is the incumbent on 75A50119F33009?
Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Mar 31, 2025.
When does Glaxosmithkline LLC’s 75A50119F33009 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 31, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75A50119F33009? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by contract number; task orders appear as independent rows.